Radiotherapy for prolactin-secreting pituitary tumors

Pituitary. 2012 Jun;15(2):135-45. doi: 10.1007/s11102-011-0348-6.

Abstract

Review the medical and surgical management of patients with prolactinomas and provide an in-depth appraisal of the role of radiotherapy in the treatment of prolactinomas. A thorough review of the pertinent literature was carried out and relevant topics were identified. Topics covered in this comprehensive review include: indications for the use of radiotherapy, choice between conventional radiotherapy and stereotactic radiosurgery, as well as the benefits and potential complications associated with each modality. Due to the excellent response rates with medical management, and rapid symptom relief afforded by resection or debulking surgery in patients who do not respond or tolerate medical therapy, radiotherapy is reserved for patients who do not respond to dopamine agonists and surgery. Both external beam radiotherapy and stereotactic radiosurgery retain important roles in the treatment of refractory or recurrent prolactinomas. Choosing the optimal approach is crucial in maximizing tumor control outcomes and minimizing the risks associated with treatment. The primary determinants of optimal radiation approach are proximity of the tumor to the optic apparatus and tumor size, with radiosurgery being our recommended treatment of choice unless the tumor is larger than 3-4 cm or within 3 mm of the optic nerves, chiasm or tracts. Optimal multidisciplinary management requires the identification of appropriate candidates for radiotherapy in order to take full advantage of treatment options available for each patient.

Publication types

  • Review

MeSH terms

  • Humans
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / radiotherapy*
  • Prolactin / metabolism*
  • Prolactinoma / metabolism
  • Prolactinoma / radiotherapy
  • Radiosurgery / methods

Substances

  • Prolactin